Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-06-17
2008-11-25
Ouspenski, Ilia (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C536S023400
Reexamination Certificate
active
07456260
ABSTRACT:
The current invention provides new human variable chain framework regions and humanized antibodies comprising the framework regions. The invention also provides a new method of identifying framework acceptor regions in framework sequences for backmutation to graft a donor sequence to the human framework.
REFERENCES:
patent: 5821337 (1998-10-01), Carter et al.
patent: 5980895 (1999-11-01), Pastan et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6255455 (2001-07-01), Siegel
patent: 6262238 (2001-07-01), Steipe et al.
patent: 6395276 (2002-05-01), Rybak et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 7037498 (2006-05-01), Cohen et al.
patent: 7084257 (2006-08-01), Deshpande et al.
patent: WO 91/09967 (1991-07-01), None
patent: WO 98/45332 (1998-10-01), None
patent: WO 98/55619 (1998-12-01), None
patent: WO 99/20749 (1999-04-01), None
patent: WO 00/61635 (2000-10-01), None
patent: WO 02/02641 (2002-01-01), None
patent: WO 02/12437 (2002-02-01), None
patent: WO 02/053596 (2002-07-01), None
patent: WO 03/027135 (2003-04-01), None
Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982, 79 : 1979-1983.
Amit et al., 1986, Science, 233: 747-753.
Al-Lazikani, Bissan, et al., “Standard conformations for the canonical structures of immunoglobulins,”J. Mol. Biol.(1997) 273: 927-948.
Arndt, Michaela A.E., et al., “A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors,”Blood(Oct. 15, 1999) 94(8):2562-2568.
Barbas III, Carlos F., et al., “Assembly of combinatorial antibody libraries on phage surfaces: The gene III site,”Proc. Natl. Acad. Sci. USA(Sep. 1991) 88: 7978-7982.
Beste, Gerald, et al., “Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold,”Proc. Natl. Acad. Sci. USA(Mar. 1999) 96: 1898-1903.
Chothia, Cyrus, et al., “Structural determinants in the sequences of immunoglobulin variable domain,”J. Mol. Biol.(1998) 278: 457-479.
Chothia, Cyrus, et al., “Structural repertoire of the human VHsegments,”J. Mol. Biol.(1992) 227 799-817.
Chothia, Cyrus, et al., “Conformations of immunoglobulin hypervariable regions,”Nature(Dec. 21-28, 1989) 342: 877-883.
Clarkson, Tim, et al. “Making antibody fragments using phage display libraries,”Nature(Aug. 15, 1991) 352: 624-628.
de Haard, Hans J.W., et al., “Absolute conservation of residue 6 of immunoglobulin heavy chain variable regions of class IIA is required for correct folding,”Protein Engineering(1998) 11(12): 1267-1276.
Jones, Peter T., et al., “Replacing the complementarity—determining regions in a human antibody with those from a mouse,”Nature(May 29, 1986) 321: 522-525.
Mansfield, Elizabeth, et al., “Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors,”Blood(Sep. 1, 1997) 90(5): 2020-2026.
Marks, James D., et al., “By-passing immunization; Human antibodies from V-gene libraries displayed on phage,”J. Mol. Biol.(1991) 222: 581-597.
McCafferty, John, et al., “Phage antibodies: filamentous phage displaying antibody variable domains,”Nature(Dec. 6, 1990) 348: 552-554.
Nygren, Per-Ake and Uhlen, Mathias, “Scaffolds for engineering novel binding sites in proteins,”Current Opinions in Structural Biology, (1997) 7: 463-469.
Orlandi, Rosaria, et al., Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,Proc. Natl. Acad. Sci. USA, (May 1989) 86: 3833-3837.
Queen, Cary, et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. USA(Dec. 1989) 86: 10029-10033.
Riechmann, Lutz, et al., “Reshaping human antibodies for therapy,”Nature(Mar. 24, 1988) 332: 323-327.
Ruiz, Manuel, et al., “IMGT, the international immunogenetics database,”Nucleic Acids Research(2000) 28(1): 219-221.
Skerra, Arne,“Lipocalins as a scaffold,”Biochimica et Biophysica Acta(2000) 1482: 337-350.
Welschof, M., et al., “Amino acid sequence based PCR primers for amplification of rearranged human heavy and light chain immunoglobulin variable region genes,”J. Immunological Methods, (1995) 179: 203-214.
Willuda, Jorg, et al., “High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment,”Cancer Research(Nov. 15, 1999) 59: 5758-5767.
de Kruif, J., et al., “New Perspectives on Recombinant Human Antibodies,”Immunology Today, vol. 17, No. 10, pp. 453-455 (Oct. 1996).
Mansfield, E., et al., “Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-Bearing Cells and Tumors,”Blood, vol. 5, No. 90, pp. 2020-2026 (Sep. 1, 1997).
Arndt Michaela
Krauss Juergen
Martin Andrew C. R.
Rybak Susanna M.
Ouspenski Ilia
The United States of America as represented by the Secretary of
The University of Reading
Townsend and Townsend / and Crew LLP
LandOfFree
Humanized antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4024667